Arovella Therapeutics Limited (ASX:ALA) has disclosed a change in the relevant interests of director David John Williams, following an on-market purchase of 53,000 ordinary shares by Moggs Creek Pty Ltd as trustee for the Moggs Creek Superannuation Fund at a price of $0.050961 per share on 17 November 2026.
Key Points
- Director David John Williams acquired 53,000 ordinary shares on-market on 17 November 2026 at $0.050961 per share
- The acquisition was made indirectly through Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund
- Following the change, Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund holds 526,354 ordinary shares and 8,000,000 performance rights
- Williams also holds an indirect interest via Lawn Views Pty Ltd ATF Angela Williams Family Trust, which maintains 200,000 ordinary shares unchanged
- The trade did not occur during a closed period requiring prior written clearance
Transaction Details and Consideration
According to the filing, the 53,000 ordinary shares were acquired via an on-market purchase at a price of $0.050961 per share. The acquiring entity is Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund, through which David John Williams holds an indirect interest by virtue of his power to exercise or control the exercise of the right to vote or dispose of shares. No securities were disposed of as part of this transaction, and no changes to contractual interests were recorded.
Securities Held Before and After the Change
Prior to the transaction, Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund held 473,354 ordinary shares and 8,000,000 performance rights in Arovella Therapeutics. Following the acquisition of 53,000 ordinary shares, that holding increased to 526,354 ordinary shares, with the 8,000,000 performance rights remaining unchanged. The separate holding through Lawn Views Pty Ltd ATF Angela Williams Family Trust remained at 200,000 ordinary shares, as disclosed in the filing.
Closed Period and Compliance Disclosure
The filing states that the interests in securities detailed in the notice were not traded during a closed period in which prior written clearance was required. As a result, no prior written clearance was necessary and no such clearance date was recorded. The notice was submitted by Arovella Therapeutics Limited under ASX listing rule 3.19A.2 and as agent for the director under section 205G of the Corporations Act. The date of the last director's interest notice for David John Williams was recorded as 17 November 2026.




Please wait processing your request...